126 related articles for article (PubMed ID: 1718379)
1. Malignant melanoma.
Smyth JF
Cancer Chemother Biol Response Modif; 1991; 12():591-602. PubMed ID: 1718379
[No Abstract] [Full Text] [Related]
2. Immunotherapy of malignant melanoma.
Oratz R; Bystryn JC
Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 and lymphokine-activated killer cell therapy in patients with relapsed B-cell lymphoma treated with rituximab.
Pitini V; Arrigo C; Naro C; Altavilla G
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5497. PubMed ID: 17875780
[No Abstract] [Full Text] [Related]
4. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of metastatic melanoma with interleukin-2].
Chosidow O; Guillaume JC
Ann Dermatol Venereol; 1992; 119(1):65-73. PubMed ID: 1373275
[No Abstract] [Full Text] [Related]
6. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy of malignant diseases].
Dorval T; Michon J; Tartour E; Fridman WH
Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
[TBL] [Abstract][Full Text] [Related]
8. Malignant melanoma.
Schwartsmann G; Parkinson DR
Cancer Chemother Biol Response Modif; 1994; 15():606-19. PubMed ID: 7779602
[No Abstract] [Full Text] [Related]
9. [Treatment of advanced melanoma with a combination of interferon and chemotherapy].
Pyrhönen S; Hahka-Kemppinen M; Muhonen T
Duodecim; 1993; 109(10):885-92. PubMed ID: 7520386
[No Abstract] [Full Text] [Related]
10. New therapies for malignant melanoma.
Hancock B
Practitioner; 1989 Oct; 233(1477):1385-6, 1388. PubMed ID: 2482487
[TBL] [Abstract][Full Text] [Related]
11. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Eisenthal A; Cameron RB; Uppenkamp I; Rosenberg SA
Cancer Res; 1988 Dec; 48(24 Pt 1):7140-5. PubMed ID: 3263900
[TBL] [Abstract][Full Text] [Related]
12. Mucosal melanoma.
Seigler HF
J Surg Oncol; 2004 Jul; 86(4):187-8. PubMed ID: 15221925
[No Abstract] [Full Text] [Related]
13. Noninterferon-based adjuvant therapy for high-risk melanoma.
Spitler LE
Expert Rev Anticancer Ther; 2002 Oct; 2(5):547-62. PubMed ID: 12382523
[TBL] [Abstract][Full Text] [Related]
14. [Cytokines and cancer: update in 1998].
Négrier S
Bull Cancer; 1999 Jan; 86(1):37-9. PubMed ID: 10029702
[No Abstract] [Full Text] [Related]
15. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
16. Current therapy for malignant melanoma.
Legha SS
Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2, killer cells and cancer therapy: an overview.
Parkinson DR; Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
[No Abstract] [Full Text] [Related]
18. The role of interleukin-2 in the biotherapy of cancer.
Parkinson DR
Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy of malignant melanoma].
Avril MF
Ann Dermatol Venereol; 1988; 115(9):959-68. PubMed ID: 2464963
[No Abstract] [Full Text] [Related]
20. [Immunotherapy of malignant melanoma].
Flageul B; Miclea JM; Bensussan A; Degos L
Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
